There is an urgent need for alternative drugs other than insulin and metformin for paediatric T2D, with liraglutide’s recent licensing and new NICE guidance for use of GLP1-RAs and SGTL2 inhibitors in paediatric T2D marking a positive step forward [54]. Here, INS is linked to type 2 diabetes mellitus.